
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. demonstrated a notable increase in Baqsimi sales, with an estimated 20% quarter-over-quarter rise in prescriptions during the third quarter of 2025, driven by a collaboration with MNKD and seasonal trends. The company's strategic expectations of maintaining a flat year-over-year top-line in 2025, followed by a return to double-digit growth in 2026, support a solid long-term outlook. Additionally, strong performance from products like Primatene Mist, particularly anticipated in the fall and winter seasons, further positions Amphastar favorably within the competitive landscape.
Bears say
Amphastar Pharmaceuticals Inc. is facing a significant decline in revenue projections for key products, notably iron sucrose and glucagon, as increased competition from generics is expected to severely impact sales. Specifically, iron sucrose sales, initially anticipated to reach $60 million annually, are now forecasted to generate only about $5 million quarterly due to market saturation and initial supply concerns, while glucagon sales projections have been adjusted downward to below $70 million starting in 2026 as the competitive landscape intensifies. Furthermore, the anticipated recovery in top-line growth expected for 2026 has been re-evaluated, suggesting a shift from double-digit gains to moderate high-single to low-double digit growth, raising further concerns about the company's future financial performance.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares